Matches in SemOpenAlex for { <https://semopenalex.org/work/W2589342322> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W2589342322 endingPage "238" @default.
- W2589342322 startingPage "238" @default.
- W2589342322 abstract "238 Background: Nintedanib (N) is an oral, triple angiokinase inhibitor of vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) receptors. This randomized, multicenter, open-label, phase II study (NCT01004003; 1199.37) evaluated the efficacy and safety of N versus sorafenib (S) in patients with advanced HCC. Methods: Enrolled patients had unresectable advanced HCC, ECOG-PS ≤2, Child–Pugh score 5–6, alanine/aspartate aminotransferase (ALT/AST) ≤2× upper limit of normal, and ≥1 untreated measurable lesion or a previously treated lesion with progression (by RECIST 1.0). Patients were randomized 2:1 to N 200 mg bid or S 400 mg bid continuously in 28-day cycles, until intolerable adverse events (AEs) or disease progression (PD); treatment beyond PD was allowed if clinical benefit was perceived. Primary endpoint was time to progression (TTP) by independent central review (ICR; RECIST 1.0), and secondary endpoints were overall survival (OS) and investigator-assessed (IA) TTP. Results: Ninety-three patients were randomized to receive N (n=62) or S (n=31). At the cutoff date (15 July 2014), 77% of patients had a TTP event, and 70% had an OS event; 3 patients remained on treatment with 1 patient beyond PD. IA TTP was comparable between N and S (median 5.5 vs 3.8 months; HR 1.05 [95% CI: 0.63–1.76]), as was OS (median 11.9 vs 11.4 months; HR 0.88 [95% CI: 0.52–1.47]). ICR TTP data are pending. All patients reported an AE (CTCAE 3.0); more patients treated with S had Grade ≥3 AEs (68% vs 90%). AEs leading to dose reduction were higher with S (19% vs 42%), whereas AEs leading to drug discontinuation were higher with N (45% vs 23%). The only tyrosine kinase inhibitor class-specific AE reported in >15% of patients was hand-foot skin reaction in the S arm. AEs previously observed with N and higher in this arm were diarrhea, vomiting, nausea, and AST increase, while blood bilirubin increase was higher with S. Rash was reported in >15% of patients only in the S arm. Conclusions: N shows similar efficacy to S with respect to TTP and OS, with a manageable safety profile. Further studies of N in patients with advanced HCC are warranted. Clinical trial information: NCT01004003." @default.
- W2589342322 created "2017-03-03" @default.
- W2589342322 creator A5004805665 @default.
- W2589342322 creator A5025272654 @default.
- W2589342322 creator A5030995134 @default.
- W2589342322 creator A5043245662 @default.
- W2589342322 creator A5043533251 @default.
- W2589342322 creator A5045513298 @default.
- W2589342322 creator A5058332899 @default.
- W2589342322 creator A5060350068 @default.
- W2589342322 creator A5072099525 @default.
- W2589342322 creator A5073880705 @default.
- W2589342322 creator A5084034524 @default.
- W2589342322 date "2015-01-20" @default.
- W2589342322 modified "2023-10-18" @default.
- W2589342322 title "Randomized phase II trial comparing the efficacy and safety of nintedanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)." @default.
- W2589342322 doi "https://doi.org/10.1200/jco.2015.33.3_suppl.238" @default.
- W2589342322 hasPublicationYear "2015" @default.
- W2589342322 type Work @default.
- W2589342322 sameAs 2589342322 @default.
- W2589342322 citedByCount "7" @default.
- W2589342322 countsByYear W25893423222015 @default.
- W2589342322 countsByYear W25893423222016 @default.
- W2589342322 countsByYear W25893423222020 @default.
- W2589342322 crossrefType "journal-article" @default.
- W2589342322 hasAuthorship W2589342322A5004805665 @default.
- W2589342322 hasAuthorship W2589342322A5025272654 @default.
- W2589342322 hasAuthorship W2589342322A5030995134 @default.
- W2589342322 hasAuthorship W2589342322A5043245662 @default.
- W2589342322 hasAuthorship W2589342322A5043533251 @default.
- W2589342322 hasAuthorship W2589342322A5045513298 @default.
- W2589342322 hasAuthorship W2589342322A5058332899 @default.
- W2589342322 hasAuthorship W2589342322A5060350068 @default.
- W2589342322 hasAuthorship W2589342322A5072099525 @default.
- W2589342322 hasAuthorship W2589342322A5073880705 @default.
- W2589342322 hasAuthorship W2589342322A5084034524 @default.
- W2589342322 hasConcept C126322002 @default.
- W2589342322 hasConcept C141071460 @default.
- W2589342322 hasConcept C168563851 @default.
- W2589342322 hasConcept C197934379 @default.
- W2589342322 hasConcept C203092338 @default.
- W2589342322 hasConcept C2776694085 @default.
- W2589342322 hasConcept C2777714996 @default.
- W2589342322 hasConcept C2778019345 @default.
- W2589342322 hasConcept C2778341716 @default.
- W2589342322 hasConcept C2778695046 @default.
- W2589342322 hasConcept C2779984678 @default.
- W2589342322 hasConcept C2780171596 @default.
- W2589342322 hasConcept C2780739268 @default.
- W2589342322 hasConcept C31760486 @default.
- W2589342322 hasConcept C535046627 @default.
- W2589342322 hasConcept C71924100 @default.
- W2589342322 hasConcept C90924648 @default.
- W2589342322 hasConceptScore W2589342322C126322002 @default.
- W2589342322 hasConceptScore W2589342322C141071460 @default.
- W2589342322 hasConceptScore W2589342322C168563851 @default.
- W2589342322 hasConceptScore W2589342322C197934379 @default.
- W2589342322 hasConceptScore W2589342322C203092338 @default.
- W2589342322 hasConceptScore W2589342322C2776694085 @default.
- W2589342322 hasConceptScore W2589342322C2777714996 @default.
- W2589342322 hasConceptScore W2589342322C2778019345 @default.
- W2589342322 hasConceptScore W2589342322C2778341716 @default.
- W2589342322 hasConceptScore W2589342322C2778695046 @default.
- W2589342322 hasConceptScore W2589342322C2779984678 @default.
- W2589342322 hasConceptScore W2589342322C2780171596 @default.
- W2589342322 hasConceptScore W2589342322C2780739268 @default.
- W2589342322 hasConceptScore W2589342322C31760486 @default.
- W2589342322 hasConceptScore W2589342322C535046627 @default.
- W2589342322 hasConceptScore W2589342322C71924100 @default.
- W2589342322 hasConceptScore W2589342322C90924648 @default.
- W2589342322 hasIssue "3_suppl" @default.
- W2589342322 hasLocation W25893423221 @default.
- W2589342322 hasOpenAccess W2589342322 @default.
- W2589342322 hasPrimaryLocation W25893423221 @default.
- W2589342322 hasRelatedWork W2000255330 @default.
- W2589342322 hasRelatedWork W2060982698 @default.
- W2589342322 hasRelatedWork W2144717536 @default.
- W2589342322 hasRelatedWork W2285208450 @default.
- W2589342322 hasRelatedWork W2886098814 @default.
- W2589342322 hasRelatedWork W2894779831 @default.
- W2589342322 hasRelatedWork W2996066981 @default.
- W2589342322 hasRelatedWork W3009513461 @default.
- W2589342322 hasRelatedWork W3165115832 @default.
- W2589342322 hasRelatedWork W4251233575 @default.
- W2589342322 hasVolume "33" @default.
- W2589342322 isParatext "false" @default.
- W2589342322 isRetracted "false" @default.
- W2589342322 magId "2589342322" @default.
- W2589342322 workType "article" @default.